Exosome RNA Exosome RNA Research & Industry News
from Alliance News By Alice Attwood
LONDON (Alliance News) – ReNeuron Group PLC said Tuesday that its core therapeutic programme remains on track toward achieving clinical milestones over the next 18 months as the company continues to search for a new Chief Executive Officer.
The Phase II efficacy study with ReN001 will recruit up to 41 stroke patients at up to ten clinical sites across the UK. “The primary endpoint is a meaningful improvement in upper limb function in disabled stroke patients six months post-stroke to a degree that would support reimbursement of the therapy by healthcare payers on a Quality Adjusted Life Year basis,” said the company.
ReNeuron also said its exosome programme is proceeding well, with pre-clinical efficacy studies underway in order to determine the disease areas to target for clinical development with exosome-based therapies in the future, and that it remains on track with plans to relocate ReNeuron’s operations to a state-of-the-art manufacturing and development facility at Pencoed, near Cardiff in South Wales, in the Spring of 2015.
The company began searching for a new CEO in April as current Chief Executive Michael Hunt prepares to move to the role of chief financial officer. Hunt will remain as chief executive until a replacement is secured.
“Our core therapeutic programmes remain on track towards further important clinical milestones over the next 18 months. In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in ReNeuron’s evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine,” said Hunt in the statement Tuesday.
By Alice Attwood; aliceattwood@alliancenews.com; @AliceAtAlliance
